Free Delivery Over $100
|
|
|||
|
||||
OverviewThis volume provides case histories illustrating the types of interdisciplinary interactions necessary to design drug candidates with optimal pharmacological, pharmaceutical, biopharmaceutical, and metabolic/pharmacokinetic properties. Key features include an incisive discussion of HIV protease inhibitors and 287 illustrations. Full Product DetailsAuthor: Ronald T. Borchardt , Roger M. Freidinger , Tomi K. Sawyer , Philip L. SmithPublisher: Springer-Verlag New York Inc. Imprint: Springer-Verlag New York Inc. Edition: Softcover reprint of the original 1st ed. 1998 Volume: 11 Weight: 0.973kg ISBN: 9781441932884ISBN 10: 1441932887 Pages: 610 Publication Date: 07 December 2010 Audience: Professional and scholarly , Professional & Vocational Format: Paperback Publisher's Status: Active Availability: Out of stock  The supplier is temporarily out of stock of this item. It will be ordered for you on backorder and shipped when it becomes available. Table of ContentsRenin Inhibitors.- The Discovery and Development of Angiotensin II Antagonists.- Development of an Orally Active Tripeptide Arginal Thrombin Inhibitor.- Discovery and Development of an Endothelin a Receptor-Selective Antagonist PD 156707.- Endothelin Receptor Antagonists.- LHRH Antagonists.- LHRH Agonists.- Discovery and Development of Somatostatin Agonists.- Factors Impacting the Delivery of Therapeutic Levels of Pyrone-Based HIV Protease Inhibitors.- The Integration of Medicinal Chemistry, Drug Metabolism, and Pharmaceutical Research and Development in Drug Discovery and Development.- De Novo Design and Discovery of Cyclic HIV Protease Inhibitors Capable of Displacing the Active-Site Structural Water Molecule.- Discovery and Development of the BHAP Nonnucleoside Reverse Transcriptase Inhibitor Delavirdine Mesylate.- Famciclovir.- The Use of Esters as Prodrugs for Oral Delivery of ?-Lactam Antibiotics.- Hematoregulators.- Discovery and Development of GG745, a Potent Inhibitor of Both Isozymes of of 5?-Reductase.- Discovery of a Potent and Selective ?1A Antagonist.- Discovery of Bioavailable Inhibitors of Secretory Phospholipase A2.- The Anxieties of Drug Discovery and Development.- CI-1015.- Orally Active Nonpeptide CCK-A Agonists.- Orally Active Growth Hormone Secretagogues.- Dorzolamide, a 40-Year Wait.- Discovery and Development of Novel Melanogenic Drugs.ReviewsAuthor InformationTab Content 6Author Website:Countries AvailableAll regions |
||||
